FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD

January 11, 2018

In This Article

New Hematology/Oncology Indications

Keytruda (pembrolizumab)

First cancer treatment approved for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

Actemra (tocilizumab)

First drug approved for giant cell arteritis.

Zelboraf (vemurafenib)

First treatment approved for Erdheim-Chester disease with BRAF V600 mutation.

Stivarga (regorafenib)

First drug approved in almost a decade for hepatocellular carcinoma.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.